AEON Biopharma, Inc. (AEON)
AEON Biopharma was planning to go public, but the IPO has been withdrawn.
Stock Price: $14.00 - $16.00
Current IPO price range
Chart not available yet
Data will show when the stock starts trading.
| Market Cap | 329.94M |
| Revenue (ttm) | 1.13M |
| Net Income (ttm) | -53.41M |
| Shares Out | 22.00M |
| EPS (ttm) | -2.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About AEON
AEON Biopharma is a clinical stage biopharmaceutical company focused on developing our proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus, Inc under the name Jeuveau. Botulinum toxins have proven to be a highly versatile therapeutic biologic, with over 230 therapeutic uses documented in published scientific literature and 10 approved therapeutic indications in the United States. Our initial devel...
IndustryPharmaceutical Preparations
Founded2012
CEOMarc Forth
Employees6
Stock ExchangeNASDAQ
Ticker SymbolAEON
Financial Performance
Financial StatementsNews
AEON Biopharma IPO Registration Document (S-1)
AEON Biopharma, Inc. has filed to go public with an IPO on the NASDAQ.
8 months ago - SEC